Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis
Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis
Background: Chinese herbal medicine is widely used in combination with usual care for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in China. Chinese patent medicine Shufeng Jiedu (SFJD) capsules is widely used for respiratory infectious diseases. This review aims to evaluate effectiveness and safety of SFJD for AECOPD. Methods: A systematic review of randomised controlled trials (RCTs) in patients with AECOPD, who received SFJD as a single intervention or as add-on treatment to usual care. PubMed, the Cochrane Library, EMBASE, Scopus, Web of Science and four Chinese databases were searched from inception to April 2019. Two authors screened trials, extracted data, and assessed risk of bias, independently. Meta-analysis was performed using RevMan 5.3 software. We performed subgroup analyses and sensitivity analyses according to the predefined protocol. Quality of evidence was assessed using GRADE. Results: Thirteen RCTs (1036 patients, with 936 inpatients) were included, all compared SFJD in combination with usual care (including antibiotics) to usual care alone. The mean age of participants ranged from 52 to 67 years, with approximately 60% male. Due to lack of blinding and other factors, all trials were of high risk of bias. SFJD was associated with a significant reduction in treatment failure, from 20.1 to 8.3% (11 trials; 815 patients; relative risk 0.43, 95% confidence interval [CI] 0.30 to 0.62), and duration of hospital stay (2 trials; 79 patients; mean difference − 4.32 days, 95% CI − 5.89 to − 2.75 days). No significant difference in adverse events was found between SFJD and control groups. Conclusion: Low certainty evidence suggests SFJD may bring additional benefit in reducing treatment failure, shorten hospital stay, and improving symptoms. Further large, high quality RCTs are needed to confirm its benefit and safety.
COPD, Chinese herbal medicine, Exacerbation, Meta-analysis, Randomised controlled trial, Shufeng Jiedu, Systematic review
Xia, Ruyu
394737f7-9ef2-4036-970e-a47eb559b737
Hu, Xiaoyang
65904b24-3775-4b14-9532-eb703a056655
Fei, Yutong
38d05d9e-30d7-48b4-b86d-768abefede0c
Willcox, Merlin
dad5b622-9ac2-417d-9b2e-aad41b64ffea
Lingzi, Wen
68cc2043-145e-4088-9182-b01577147308
Yu, Ming-Kun
2d737e60-76c3-462b-9439-f38b76e4073f
Lishan, Zhang
fef99d72-4c05-4e9b-a2e7-26d5d3f60dd2
Dai, Meng-Yuan
b99d8335-7c45-490a-ae0c-e7161642f3d2
Fei, Guang-He
fb569fe1-9db1-44e8-91b6-a56c7efde2d9
Thomas, Mike
997c78e0-3849-4ce8-b1bc-86ebbdee3953
Francis, NA
9b610883-605c-4fee-871d-defaa86ccf8e
Wilkinson, Thomas
8c55ebbb-e547-445c-95a1-c8bed02dd652
Moore, Michael
1be81dad-7120-45f0-bbed-f3b0cc0cfe99
Liu, Jianping
4699004b-2872-49f2-b2f9-f90a061a29db
24 May 2020
Xia, Ruyu
394737f7-9ef2-4036-970e-a47eb559b737
Hu, Xiaoyang
65904b24-3775-4b14-9532-eb703a056655
Fei, Yutong
38d05d9e-30d7-48b4-b86d-768abefede0c
Willcox, Merlin
dad5b622-9ac2-417d-9b2e-aad41b64ffea
Lingzi, Wen
68cc2043-145e-4088-9182-b01577147308
Yu, Ming-Kun
2d737e60-76c3-462b-9439-f38b76e4073f
Lishan, Zhang
fef99d72-4c05-4e9b-a2e7-26d5d3f60dd2
Dai, Meng-Yuan
b99d8335-7c45-490a-ae0c-e7161642f3d2
Fei, Guang-He
fb569fe1-9db1-44e8-91b6-a56c7efde2d9
Thomas, Mike
997c78e0-3849-4ce8-b1bc-86ebbdee3953
Francis, NA
9b610883-605c-4fee-871d-defaa86ccf8e
Wilkinson, Thomas
8c55ebbb-e547-445c-95a1-c8bed02dd652
Moore, Michael
1be81dad-7120-45f0-bbed-f3b0cc0cfe99
Liu, Jianping
4699004b-2872-49f2-b2f9-f90a061a29db
Xia, Ruyu, Hu, Xiaoyang, Fei, Yutong, Willcox, Merlin, Lingzi, Wen, Yu, Ming-Kun, Lishan, Zhang, Dai, Meng-Yuan, Fei, Guang-He, Thomas, Mike, Francis, NA, Wilkinson, Thomas, Moore, Michael and Liu, Jianping
(2020)
Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis.
BMC Complementary and Alternative Medicine, 20 (1), [151].
(doi:10.1186/s12906-020-02924-5).
Abstract
Background: Chinese herbal medicine is widely used in combination with usual care for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in China. Chinese patent medicine Shufeng Jiedu (SFJD) capsules is widely used for respiratory infectious diseases. This review aims to evaluate effectiveness and safety of SFJD for AECOPD. Methods: A systematic review of randomised controlled trials (RCTs) in patients with AECOPD, who received SFJD as a single intervention or as add-on treatment to usual care. PubMed, the Cochrane Library, EMBASE, Scopus, Web of Science and four Chinese databases were searched from inception to April 2019. Two authors screened trials, extracted data, and assessed risk of bias, independently. Meta-analysis was performed using RevMan 5.3 software. We performed subgroup analyses and sensitivity analyses according to the predefined protocol. Quality of evidence was assessed using GRADE. Results: Thirteen RCTs (1036 patients, with 936 inpatients) were included, all compared SFJD in combination with usual care (including antibiotics) to usual care alone. The mean age of participants ranged from 52 to 67 years, with approximately 60% male. Due to lack of blinding and other factors, all trials were of high risk of bias. SFJD was associated with a significant reduction in treatment failure, from 20.1 to 8.3% (11 trials; 815 patients; relative risk 0.43, 95% confidence interval [CI] 0.30 to 0.62), and duration of hospital stay (2 trials; 79 patients; mean difference − 4.32 days, 95% CI − 5.89 to − 2.75 days). No significant difference in adverse events was found between SFJD and control groups. Conclusion: Low certainty evidence suggests SFJD may bring additional benefit in reducing treatment failure, shorten hospital stay, and improving symptoms. Further large, high quality RCTs are needed to confirm its benefit and safety.
This record has no associated files available for download.
More information
Accepted/In Press date: 14 April 2020
Published date: 24 May 2020
Additional Information:
Funding Information:
This work was supported by the National Key Research and Development Project (grant no. 2018YFE0102300) and Innovate UK (grant no. 104287? 610239). Merlin Willcox?s salary is funded by NIHR Academic Clinical Lectureship, under grant CL-2016-26-005. The funding sources had no role in the design of the study and collection, analysis, and interpretation of the data and in writing the manuscript.
Publisher Copyright:
© The Author(s). 2020.
Keywords:
COPD, Chinese herbal medicine, Exacerbation, Meta-analysis, Randomised controlled trial, Shufeng Jiedu, Systematic review
Identifiers
Local EPrints ID: 441290
URI: http://eprints.soton.ac.uk/id/eprint/441290
ISSN: 1472-6882
PURE UUID: 02ad6ad1-b58f-46eb-be2a-c7d728e4c5de
Catalogue record
Date deposited: 08 Jun 2020 16:32
Last modified: 17 Mar 2024 03:58
Export record
Altmetrics
Contributors
Author:
Ruyu Xia
Author:
Yutong Fei
Author:
Wen Lingzi
Author:
Ming-Kun Yu
Author:
Zhang Lishan
Author:
Meng-Yuan Dai
Author:
Guang-He Fei
Author:
Jianping Liu
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
